Karnataka orders actual medicine costs on patient bills

Karnataka has ordered hospitals and medicine sellers to show procurement cost, MRP and patient price on bills from November 1. The move aims to improve billing transparency, though industry and patient groups say enforcement and wider supply-chain tracking will matter.Karnataka has become the first Indian state to mandate disclosure of the actual procurement cost, or landing price, of medicines, medical devices and consumables alongside their maximum retail price (MRP) and the amount charged to patients.The state’s Food Safety and Drugs Administration (FDA) has directed hospitals, healthcare institutions and medicine retailers to make these prices visible on patient bills from November 1, bringing a long-standing concern over healthcare pricing into sharper focus.The circular seeks to address the gap between what hospitals pay to procure products and what patients are charged. It says patients are, in several cases, billed at or near the MRP without being told the actual acquisition cost.The disclosure requirement is intended to improve transparency, protect patients and help identify unfair trade practices. The directive covers government, private and trust hospitals, nursing homes, clinics, day-care centres and diagnostic centres. It also extends to clearing and forwarding agents, stockists, distributors, wholesalers and retailers licenced by the state FDA. Under the new requirements, every patient must receive an itemised bill listing medicines, medical devices, implants, consumables and disposables separately.Each applicable line item must carry the product’s name, batch number, manufacturing and expiry dates, landing or base price, MRP, price charged to the patient and applicable taxes. The price charged cannot exceed the MRP. The move comes amid sustained scrutiny of medicine and medical-device pricing. A parliamentary committee had recently flagged concerns about the gap between the cost of medical products and the prices ultimately charged to patients, highlighting the need for greater transparency and stronger oversight of trade margins.The Maharashtra Food and Drug Administration later also raised concerns over substantial mark-ups on medical products supplied to hospitals. Such scrutiny has brought attention to a wider problem: even where the MRP is legally displayed, patients may have little information about the price at which a hospital acquired the product.The Supreme Court, too, has questioned the government over hospital and medicine pricing.Following the pressure, the government just days ago fixed a 30% trade margin for non-scheduled cancer medicines and has now also been asked to extend the same to all non-patented medicines.WILL TRANSPARENCY CUT BILLS?Karnataka FDA order’s immediate impact will depend on implementation, say those advocating patients’ rights.Disclosure can help patients compare bills, question unexplained charges and give regulators a clearer basis for investigating unusually high mark-ups. However, showing the procurement price does not automatically make a product cheaper, nor does it guarantee that patients can choose a lower-cost alternative during treatment, they argue.The Association of Indian Medical Device Industry (AiMeD) – a network of Indian device makers, meanwhile, has also welcomed the initiative, describing it as a positive step towards patient awareness, informed decision-making and greater accountability in healthcare billing.But the industry body argues that transparency must extend beyond the hospital counter to capture the entire supply chain.“We appreciate the Karnataka Government's efforts to bring greater transparency to healthcare billing and trade margins,” said Rajiv Nath, forum coordinator at AiMeD.He said disclosure at the hospital level captures only the margin at the final point of supply, making it difficult to determine where excessive mark-ups originate.AiMeD wants pricing tracked from the first point of sale, starting with the import landed price or the manufacturer's selling price, and continuing through distributors, wholesalers, retailers and hospitals. Recording transaction values at each stage, it argues, would help regulators identify where prices escalate and design corrective measures based on evidence rather than focusing on a single stakeholder.The association has also called on the Department of Pharmaceuticals to hold stakeholder consultations and conduct pilot projects before introducing wider trade-margin rationalisation measures.- Ends